GlassScriptPhysician profile
Michael A Nakao
NPI 1538169404
$2,463.50
in general payments reported to CMS, 2019-2025
17 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2021: $99.73 · 2023: $506 · 2024: $702 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $450.47 | 2019-2024 | Fasenra, Imfinzi |
| United Therapeutics Corporation | $304.84 | 2024-2025 | Tyvaso |
| Pulmonx Corporation | $288.89 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.56 | 2023-2025 | Ofev |
| Glaxosmithkline, LLC. | $195.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Verona Pharma, INC. | $185.98 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $122.88 | 2024 | Keytruda |
| Harmony Biosciences LLC | $112.52 | 2024 | |
| Jazz Pharmaceuticals INC. | $101.88 | 2025 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Pharming Healthcare, INC. | $95.43 | 2023 | Joenja |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Electromed, INC. | $46.79 | 2021-2025 | Smartvest |
| Lilly USA, LLC | $41.23 | 2025 | Zepbound, Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $31.98 | 2025 | Lumryz |
| Ani Pharmaceuticals, INC. | $20.97 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nakao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.